Key result
Promoting physiological hypertrophy in the failing heart, potentially via the insulin-like growth factor 1-phosphoinositide-3-kinase pathway, may be beneficial for improving cardiac function.
Answers are grounded in this paper and cite their sources.
This mini-review highlights the potential therapeutic benefit of promoting physiological hypertrophy, such as through the IGF-1-PI3K pathway, in the failing heart.
Heart failure rates have reached epidemic proportions in Western society. 2. New strategies proposed to improve cardiac function of the failing heart include regeneration, stem cell therapy, innovative methods for the revascularization of ischaemic cardiac tissue and the activation of signalling pathways that promote physiological growth (hypertrophy). 3. The insulin-like growth factor 1-phosphoinositide-3-kinase pathway is a well characterized regulator of physiological hypertrophy. 4. In this mini-review we present studies that suggest promoting physiological hypertrophy in the failing heart may be beneficial.
No takes yet. Share an insight, caveat, or question.
Pretorius et al. (2008) conducted a review in Heart failure. Promoting physiological hypertrophy was evaluated. Promoting physiological hypertrophy in the failing heart, potentially via the insulin-like growth factor 1-phosphoinositide-3-kinase pathway, may be beneficial for improving cardiac function.
Synapse has enriched 10 related papers. Consider them for comparative context: